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Abstract
Microbeam radiation therapy (MRT) is a promising preclinical modality for cancer treatment, with 
remarkable preferential tumoricidal effects, that is, tumor eradication without damaging normal 
tissue functions. Significant lifespan extension has been demonstrated in brain tumor-bearing 
small animals treated with MRT. So far, MRT experiments can only be performed in a few 
synchrotron facilities around the world. Limited access to MRT facilities prevents this enormously 
promising radiotherapy technology from reaching the broader biomedical research community and 
hinders its potential clinical translation. We recently demonstrated, for the first time, the feasibility 
of generating microbeam radiation in a laboratory environment using a carbon nanotube x-ray 
source array and performed initial small animal studies with various brain tumor models. This new 
nanotechnology-enabled microbeam delivery method, although still in its infancy, has shown 
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promise for achieving comparable therapeutic effects to synchrotron MRT and has offered a 
potential pathway for clinical translation.
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Brain cancer & radiation therapy
Brain cancer is one of the most aggressive terminal diseases despite significant effort and 
advancement in anticancer treatment. The median survival time for patients with 
glioblastoma multiforme, the most common and lethal form of brain tumor, is 15 months 
after diagnosis. There has been only minimal improvement over the past 50 years, even with 
aggressive multimodality treatments [1,2]. Almost all high-grade gliomas recur and there is 
virtually no long-term survival [3]. Currently, radiotherapy is used in conjunction with 
surgery and chemotherapy as the standard of care for brain cancer patients [4]. Modern 
radiation therapy (RT) techniques, such as intensity-modulated radiation therapy and 
stereotactic radiosurgery, strive to achieve dose conformality to the tumor target and 
minimal dose deposition to surrounding critical structures.
However, none of those focal RT techniques have been shown to be successful in achieving 
effective tumor control and in 90% of the cases tumors reoccur at the primary site [5,6]. One 
of the main reasons is that most malignant brain cancers are highly aggressive and 
infiltrative, that is, the tumor cells are highly proliferating and tend to invade into normal 
brain, leaving no well-defined margins between the tumor and surrounding normal tissue. 
This poses a great challenge in radiotherapy to minimize treatment toxicity to critical normal 
brain tissue and the CNS when a large planning target volume must be covered by high 
levels of radiation dose for complete tumor ablation. It is even more of an issue in treating 
radiation-sensitive pediatric brain cancer patients.
Microbeam radiation therapy
Microbeam radiation therapy (MRT) is a new treatment modality that is different from 
conventional external beam RT. Instead of depositing homogeneous radiation dose with a 
continuous broadbeam throughout the entire treatment region, MRT employs spatially 
fractionated, planar x-ray beams that range from 20 mm to a few hundred microns wide, 
separated by a distance several times of their beamwidth (FIGURE 1) [7–11]. These quasi-
parallel orthovoltage microplanar beams deliver, within a single fraction, two orders of 
magnitude higher dose than that used in conventional RT. These microbeams create unique 
dose profiles of alternating peaks and valleys with high peak-to-valley-dose-ratios (PVDR) 
[12,13]. Synchrotron-based MRT studies using small animal tumor models have 
convincingly demonstrated that normal tissue can be well preserved and recover from 
radiation even at extremely high peak doses. This was achieved while simultaneously 
suppressing the growth of tumor tissue, or completely eradicating the tumor, in some cases 
[14–18]. The median survival time of MRT-treated small animals can be improved tenfold 
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compared to untreated controls [19]. The tumor tissue selectivity makes MRT an attractive 
modality for treatment of brain malignancies.
High peak dose for tumor eradication and low valley dose for normal tissue tolerance in 
submillimeter length scale are essential characteristics of the MRT dosimetry. This is, 
however, difficult to achieve with current commercial radiation sources. The clinically used 
mega-voltage linear accelerators create a large number of scattered, secondary charged 
particles in tissue, which, as a result, makes it difficult to retain a sharp beam profile (small 
penumbras) and high PVDR. Conventional orthovoltage x-ray tubes generate broad and 
divergent radiation with flux limited by anode heat management. To obtain the desired 
microbeam pattern with sufficiently high PVDR, a collimator with a narrow opening and a 
large aspect ratio must be applied to the intrinsically divergent beam, which blocks an 
overwhelming majority of the x-ray photon flux and results in a much reduced microbeam 
dose rate. The output power of conventional microfocus x-ray tubes with submillimeter 
focal spot sizes is significantly lower than what is needed for MRT [20–22].
The ability of MRT to outperform conventional broadbeam RT has been demonstrated by 
several synchrotron-based studies. Dilmanian et al. irradiated a group of 9L gliosarcoma-
bearing rats with microbeams of various pitches and dose levels and compared them with 
the broadbeam-treated group [15,23]. The median survival time of all the MRT-treated 
groups was significantly longer than the broadbeam RT group. In another study with EMT-6 
carcinoma-bearing mice, an improved therapeutic index was shown in the coplanar 
microbeam irradiated groups compared to the broadbeam-treated group [7].
Nanotechnology enables a compact microbeam delivery system
We developed a spatially distributed field emission x-ray source array technology using 
carbon nanotubes (CNT) [24] [25–27]. In contrast to the current thermionic x-ray sources, it 
uses an electric field to extract electrons from one or multiple CNT cathodes at room 
temperature, which are focused and accelerated to bombard an anode to generate x-ray 
radiation. The field emission technology opens up new possibilities in x-ray source design 
that are not easily accessible with the thermionic sources, including arrays with different 
source configurations and electronically programmable radiation. The medical applications 
of this technology have been demonstrated in high-resolution dynamic micro-CT [28]; 
stationary digital breast tomosynthesis [29,30], which is currently in clinical trial [31] and 
tomosynthesis guidance for radiotherapy [32].
With the distributed source array design, the electron beam can be spread from a single focal 
spot into one or multiple long and narrow focal tracks to increase the microbeam dose rate. 
The concept is illustrated in FIGURE 2 in a ring-shaped configuration. Each x-ray source 
segment delivers a microbeam array to the tumor target, directed from different angles [27]. 
This is in essence equivalent to having a large number of high-power x-ray tubes irradiating 
an object simultaneously without the constraint of space, cost, power consumption and 
alignment difficulties. In addition to increased microbeam dose rate, the ring-shaped 
configuration is advantageous for human MRT where a high target dose and high beam 
mean energy is required. Such design can effectively reduce the valley dose at the entrance 
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and the toxicity to skin and subcutaneous tissue by distributing the total entrance dose over a 
larger skin area compared to the fixed, unidirectional configuration of synchrotron sources.
The x-ray radiation from a CNT source array is electronically controlled, and each source 
can be switched on and off individually and near-instantaneously. Such features ensure 
reliable radiation beam delivery and meet the clinical requirement for RT systems in terms 
of safety and reliability. The programmable sources allow physiologically gated radiation 
delivery, where radiation exposure is synchronized with the respiratory and cardiac signals, 
to minimize motion-induced microbeam blur during treatment [33,34].
A compact image-guided MRT prototype for small animal models
The first proof-of-principle device, as shown in FIGURE 3, employs a single linear CNT source 
array which projects a long and narrow focal track (162 ×.14 mm) on a stationary tungsten 
anode [35]. A motorized microbeam collimation and alignment assembly aligns a 175 μm 
slit with the anode focal line and collimates the primary beam into a microbeam of 
adjustable width. The first prototype operates at 160 kVp anode voltage and 30 mA tube 
current, generating a 280 μm wide microbeam at the sample entrance plane (124 mm 
downstream from the focal track). The average microbeam dose rate is 1.2 Gy/min at the 
sample entrance plane [36]. Parallel microbeams are delivered by translating the sample 
perpendicularly to the beam plane in a step-and-shoot manner. An example of the 
microbeam pattern recorded by a Gafchromic EBT2 film (Ashland Advanced Materials, 
KY, USA) is shown in FIGURE 4. Three microbeams (280 μm wide) were delivered at 900 μm 
center-to-center distance yielding a PVDR of 16 [36,37]. This is well within the typical 
PVDR range that has been shown sufficient for retaining the normal tissue sparing effect in 
synchrotron MRT experiments [11,15]. More specifications of the first CNT-based MRT 
prototype is listed in TABLE 1.
Target identification and localization are critical for treatment planning and accurate dose 
delivery. This has not been fully addressed in previous synchrotron MRT experiments; no 
comprehensive image-guidance protocol for tumor visualization and targeting has been 
reported. A few recent studies have investigated the use of planar x-ray radiography [38,39] 
or propagation-based phase contrast portal imaging [40] as guidance for MRT, either for the 
tumor injection point or specific skull bony-landmark-based verifications. In our prototype, 
a high-resolution micro-CT scanner was integrated with the microbeam irradiator to 
facilitate target identification and accurate microbeam delivery. This micro-CT scanner 
contains a micro-focused CNT x-ray source and provides an image resolution of up to 70 μm 
[28]. The CT rotation isocenter is aligned with the microbeam treatment platform, and a 
connecting high-precision translation stage transports the sample to the microbeam 
treatment site after imaging. Generally, CT images are not ideal for brain tumor 
visualization due to beam hardening through the skull and the resultant low soft tissue 
contrast. A considerable dose of contrast agent is often required, which causes 
nephrotoxicity and complicates the treatment outcome. As a result, MRI is used for tumor 
visualization, and on-board x-ray imaging is used for skull structures and landmark 
localization. Registered images from the two modalities are used to identify the tumor, 
determine the microbeam treatment coordinates and plan treatment accordingly (FIGURE 
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5). A detailed protocol with 2D imaging and registration was previously reported [36]. 
Briefly, animals undergo MRI scans (9.4T MR scanner, Bruker BioSpin Corp., MA, USA) 
the day before MRT to delineate the tumor and find its location. x-ray imaging is performed 
prior to treatment to capture the bone structures and landmarks on the mouse bed. Animals 
are anesthetized and immobilized the same way on a customized mouse bed for both MRI 
and x-ray imaging. The MR images and x-ray radiographs are registered using a 2D rigid-
body method to present the tumor location relative to the skull and landmarks. With the 
landmarks precalibrated as a reference to the microbeam location, the registered images 
provide the tumor coordinates in the microbeam treatment space, and enable accurate 
delivery of microbeams to the tumor target. Using brain tumor-bearing mice models, a 
microbeam targeting accuracy of 450 μm has been accomplished (FIGURE 6). This fast 
procedure allows for imaging and irradiating two animals simultaneously to improve the 
experimental throughput.
Preliminary animal studies with brain tumor-bearing mice
Small animal studies have been carried out including tumor growth control and survival 
studies with U87MG human glioma-bearing mice and radiobiological studies with 
medulloblastoma-bearing mouse pups. A variety of characterization techniques, including 
MRI and immunohistological bio-markers such as γ-H2AX, cleaved caspace-3, Ki67 and 
F4/80, were used to facilitate the interpretation of MRT radiobiology at the cellular level. In 
a study with U87 human glioma-bearing mice, arrays of single or multiple microbeams of up 
to 138 Gy/beam were delivered to the 2-mm (average diameter) brain tumors, with a tumor 
targeting accuracy of around 450 μm [36]. As shown in FIGURE 6, microbeam radiation-induced 
DNA double-strand breaks were clearly characterized histologically on γ-H2AX-stained 
brain sections collected after animal euthanization. Pink stripes of γ-H2AX-positive cells 
corresponded to the tracks of microbeam peaks across the brain tumors. The beamwidth on 
the stained tissue, measured by the mean full-width-half-maximum, was 350 μm. This was 
broader than the 280 mm beamwidth measured by Gafchromic EBT2 film at the mouse skin 
entrance, but slightly narrower than the exit beamwidth (380 μm). Beam center-to-center 
distance from the histology was 800 μm. Measurements from the histology matched well 
with the planned beam pitch and film results, when considering tissue distortion and the 
20% anisotropic shrinkage during tissue processing [41]. In another study using the same 
animal models, γ-H2AX expression was measured at 1, 4, 24 and 48 h after MRT and also at 
7 days. Strong γ-H2AX signal was observed at the early hours, and the expression reduced 
over time in both tumor and normal tissue. After 7 days, γ-H2AX expression was still 
detected, although very weak. Quantitatively, higher level of γ-H2AX expression was 
observed in the tumor region compared to that in normal tissue. The expression in tumor 
after 48 h was well dispersed with no clear delineation between peak and valley regions, 
whereas in normal tissue weak γ-H2AX signals were only detected on the beam tracks.
In another study with U87 tumor mice, a significant decrease in the tumor growth rate was 
seen in the mice treated with microbeams compared to the nontreated sham control (FIGURE 7) 
[42]. Twenty young-adult athymic nude mice inoculated with U87MG human glioma tumor 
cells were grouped to receive different treatments. They were unidirectional two 
microbeams radiation with 48 Gy, 66 Gy, 72 Gy or 100 Gy peak entrance doses; two 
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orthogonally cross-fired arrays of four microbeams (crossbeam) with 50 Gy peak entrance 
dose and 10 Gy whole-brain broadbeam RT using a 6 MV clinical LINAC (Siemens Corp., 
Germany). The microbeams used in all MRT groups were approximately 300 μm wide and 
separated by 900 μm center-to-center distance. T2-weighted MRI volumetric results (FIGURE 7) 
pre- and post-treatment indicated that higher peak entrance doses produced more prominent 
tumor growth suppression. Animals treated with unidirectional high-dose MRT showed 
similar tumor growth delay compared to the conventional RT-treated group. Particularly, a 
better tumor local control was achieved in the group treated with crossbeam high-dose MRT 
(FIGURE 8).
Cardiac and respiration-induced brain motion in humans can range from a few hundred 
microns to 1 mm [43,44], which is similar to or even wider than the microbeams. To avoid 
beam blurring and/or false targeting caused by motion, it is necessary to either complete the 
treatment within a time window much shorter than the motion cycle or synchronize radiation 
exposure with the physiological motion. The former approach is used at the synchrotron 
MRT facilities where the dose rate can exceed 103 Gy/s. Physiological gating eliminates the 
need for this extraordinarily high dose rate that causes safety concerns and cannot be 
achieved by non-synchrotron radiation sources. The feasibility of physiologically gated 
micro-beam irradiation was recently demonstrated in vivo, for the first time, using our CNT-
based MRT system [33,34]. The respiratory signals of an anesthetized mouse were recorded 
with a sensor, which triggered the microbeam radiation exposure during a specific phase of 
the respiratory cycle. Histological results showed that gated irradiation can effectively 
reduce motion-induced beam broadening and improve the overall PVDR [34].
Expert commentary & five-year view
The research on MRT has been limited to a few synchrotron facilities around the world since 
the beginning in 1960s, due to the lack of appropriate non-synchrotron delivery 
technologies. The novel CNT x-ray source array makes it possible to develop, for the first 
time, compact laboratory-scale MRT systems for cancer research and provides a potential 
pathway for clinical translation. Compared to the current synchrotron-based MRT facilities, 
CNT-based MRT also has several intrinsic advantages, including orders of magnitude lower 
in dimensions and cost. The physiologically gated irradiation minimizes motion-induced 
microbeam blur and eliminates the need for the ultra-high dose rate, which is a concern for 
patient safety. The surrounding source design (as shown in FIGURE 2) with conformal 
collimation can provide a more desirable dose profile than the unidirectional beam, resulting 
in a higher energy deposited on the tumor than on the skin [45]. Different micro-beam 
treatment patterns such as interlaced microbeams can be generated in a single fraction 
without patient translation or rotation.
The results, so far, show that the essential dosimetry characteristics that are considered 
necessary for the unique preferential tumoricidal effects of MRT – including beam energy, 
beam width and PVDR – can be generated by the CNT-based MRT system. Preliminary 
studies using small animal models have shown promising therapeutic effects in terms of 
tumor local control and survival rate extension. The research is still in its infancy and the 
technology needs further development. The first-generation prototype produces a single 
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microbeam at a low average microbeam dose rate due to the limit of the anode heat 
dissipation capability. The low dose rate limits the experimental output and poses challenges 
in animal anesthetization and immobilization. The mean beam energy of the prototype is 
approximately 60 keV, lower than the value used in the synchrotron MRT which is typically 
around 100 keV. Additionally, the beamwidth from the first prototype is 280 μm, which is 
slightly wider than the typical 25–75 μm beamwidth used in early synchrotron studies. 
However, there have been many reports that demonstrated similar therapeutic effects with 
larger size microbeams (up to 700 μm wide) [8,9,46–48]. Our beamwidth is well within the 
size range that has been shown to retain the MRT therapeutic effects.
A second-generation system has been designed and is being assembled and tested. The new 
CNT source array has a significantly increased anode heat capacity. It will be able to 
generate multiple parallel microbeams with an anticipated 20-times increase in the dose rate 
and a higher x-ray mean energy compared to the first-generation system. The higher flux 
allows delivery of a total MRT dose comparable to that used in synchrotron MRT studies, 
within an acceptable time window.
To translate MRT from a highly promising radiotherapy technology for experimental small 
animal studies to patient treatment, many challenges and unanswered questions need to be 
first addressed. In the next 5 years, we expect that the potential of MRT for large animal and 
human treatment will be evaluated at synchrotron facilities, and we will continue the 
development of laboratory-scale MRT systems to facilitate the research and translation of 
this promising technology. After many years of comprehensive research using small animal 
models, the group at the European Synchrotron Radiation Facility has initiated a study using 
brain tumor-bearing larger animals including dogs and cats [49,50]. This is a major step 
toward patient treatment. It remains to be seen whether the MRT preferential therapeutic 
effects are maintained in larger animals. Optimization of the corresponding dosimetric 
parameters to adapt to larger treatment targets will be also needed.
Although MRT as an experimental RT modality has been studied for several decades, today 
it remains an unfamiliar technique to most medical physicists and radiation oncologists, and 
is pursued only by a few research groups with access to the limited number of synchrotron 
facilities around the world. We hope the availability of this compact and economically 
viable MRT technology will encourage more researchers to investigate this promising 
radiotherapy technique and expedite its potential clinical translation.
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• Brain tumors, especially glioblastoma multiforme, are among the most deadly 
cancers. So far, there has been no effective treatment to significantly extend the 
patients’ mean survival. Clinically used RT modalities often cause intolerable 
normal tissue toxicity to the circumjacent critical brain structures and the CNS.
• Microbeam radiation therapy (MRT) in small animal tumor models has shown 
strong tumor killing and normal tissue sparing effects.
• Until now, MRT research can only be carried out at a few remote synchrotron 
facilities and the therapeutic mechanism behind is still unclear. Widely 
accessible microbeam irradiators that can be readily installed in laboratories and 
medical centers are needed.
• Carbon nanotube (CNT) x-ray technology overcomes some of the limitations of 
conventional orthovoltage tubes and is the core of our technique for developing 
a compact MRT system for preclinical and, ultimately, clinical use.
• Utilizing the CNT source array, a prototype CNT-based microbeam irradiator 
has been developed and calibrated for preclinical studies.
• An MRI/x-ray combined image guidance protocol has been demonstrated to 
achieve a targeting accuracy of 450 mm in brain tumor mouse models.
• Preliminary studies in U87MG human glioma-bearing mice using the CNT 
MRT prototype have shown significant tumor growth suppression in MRT-
treated groups compared to nontreated controls.
• Gated MRT is feasible using our proof-of-concept MRT prototype. It has been 
shown to be effective in reducing motion-induced microbeam blurring.
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Left: SolidWorks drawing of an array of microbeams irradiating the mouse brain. Right: 
Illustration of idealized microbeam radiation therapy dose distribution with alternating peaks 
and valleys and a high peak-to-valley-dose-ratio. The beam width measured in FWHM is 
usually around 25 μm or up to 700 μm. FWHM: Full-width-half-maximum.
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A conceptual SolidWorks drawing of a ring-structure human carbon nanotube-microbeam 
radiation therapy system, where microbeams come from multiple ports and are directed 
toward the treatment target simultaneously.
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Left: A photo of the first prototype image-guided microbeam irradiation system in our lab. 
Right: A SolidWorks drawing illustrating our first prototype carbon nanotube microbeam 
radiation therapy system which consists of a single array of carbon nanotube x-ray source. 
Electron beam generation, x-ray microbeam collimation and the microbeam irradiating a 
mouse head have been indicated. Reproduced with permission from [36].
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Dose profile at entrance plane of U87 tumor mice microbeam radiation therapy, recorded by 
Gafchromic EBT2 film and analyzed using FilmQAPro program (multi-channel dosimetry) 
(Ashland Advanced Materials, KY, USA). The peak-to-valley-dose-ratio was measured to 
be 16 with 280-μm wide microbeams separated at 900 μm center-to-center distance. FWHM: 
Full-width-half-maximum.
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Left: A 2D registered image of MR image and X-ray radiograph, with three microbeams 
planned to irradiate across the tumor area; Right: a picture of U87 glioma-bearing mouse 
fully stabilized on the homemade holder with ear bar and teeth fixation. Gafchromic EBT2 
film was used at the microbeam entrance and exit plane for dosimetry confirmation 
purposes.
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γ-H2AX staining of the brain tissue collected from the tumor mouse treated with two-beam 
microbeam radiation therapy. The animal was sacrificed and the brain was collected and 
fixed 4 h after radiation finished. Reproduced with permission from [33].
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MRI volumetric data showing the relative tumor volume growth of U87 glioma-bearing 
mice a week after receiving different treatments. Notice the trend of decreased growth rate 
with increasing MRT peak entrance dose. Notice the animal treated with crossbeam MRT 
showed minimum relative tumor growth. Conv. RT: Conventional radiation therapy; MRT: 
Microbeam radiation therapy.
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Volumetric data from T2-weighted MRI of two U87 glioma-bearing mice treated with 
crossbeam microbeam radiation therapy (top) and conventional whole brain broadbeam 
radiation therapy (bottom).
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Table 1
Specifications of the first prototype CNT-based MRT system.
Parameters CNT-based MRT
Number of CNT source arrays 1
Anode voltage 160 kV
Tube current 30 mA
Focal track width 131 μm





† 17 (beam separation 900 μm)
On-board imager Micro-CT
Physiological gating capability Yes
CNT: Carbon nanotube; MRT: Microbeam radiation therapy; PVDR; Peak-to-valley-dose-ratio.
†
Measured at 124 mm from the focal track on the anode.
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